Lymphocyte Membrane Antigen Receptors Reside in Discrete Protein Islands
|
By LabMedica International staff writers Posted on 27 Sep 2015 |

Image: Researchers previously assumed that receptors such as the antigen receptors of class Immunoglobulin M and Immunoglobulin D are freely diffusing and equally distributed molecules on the membrane. However, the new study shows that these antigen receptors are organized in different membrane compartments, also called \"protein islands\", with diameters of 150–200 nanometers (Photo courtesy of Reth Research Group, BIOSS Centre for Biological Signaling Studies of the University of Freiburg).
By applying several advanced imaging techniques, researchers have resolved the distribution of B-cell antigen receptors on the membranes of immune system lymphocytes.
The B-cell antigen receptors (BCRs) play an important role in the clonal selection of B-cells and their differentiation into antibody-secreting plasma cells. Mature B-cells have both immunoglobulin M (IgM) and IgD types of BCRs, which have identical antigen-binding sites and are both associated with the signaling subunits Ig-alpha and Ig-beta, but differ in their membrane-bound heavy chain isoforms.
Investigators at the BIOSS Centre for Biological Signaling Studies of the University of Freiburg (Germany) applied, two-color direct stochastic optical reconstruction microscopy (dSTORM), transmission electron microscopy (TEM), and the Fab-based proximity-ligation assay (Fab-PLA) to resolve the location and distribution of BCRs in the mature lymphocyte membrane.
Results published in the September 15, 2015, issue of the journal Science Signaling revealed that in contrast to the assumption that BCRs—like all proteins in the membrane—were freely diffusing molecules, dSTORM showed that IgM-BCRs and IgD-BCRs resided in the plasma membrane in different protein islands with average sizes of 150 and 240 nanometers, respectively. Upon B-cell activation, the BCR protein islands became smaller and more dispersed such that the IgM-BCRs and IgD-BCRs were found in close proximity to each other. Moreover, specific stimulation of one class of BCR had minimal effects on the organization of the other. These conclusions were supported by the findings from two-marker transmission electron microscopy and proximity ligation assays.
These results provide direct evidence for the nanoscale compartmentalization of the lymphocyte membrane. In addition, they suggest that upon B-cell activation, the different IgM and IgD protein islands form complexes, which allow the exchange of lipids and proteins. This could be the basis for the association of IgM with Raft-associated lipids and proteins, which is a well-known hallmark of B-cell activation.
The current study was a component of the University of Frieberg's BIOSS nanoscale explorer program (BiNEP), which is dedicated to developing better methods to resolve nano-structures that are smaller than the 250 nanometer diffraction limit of visible light.
Related Links:
BIOSS Centre for Biological Signaling Studies of the University of Freiburg
The B-cell antigen receptors (BCRs) play an important role in the clonal selection of B-cells and their differentiation into antibody-secreting plasma cells. Mature B-cells have both immunoglobulin M (IgM) and IgD types of BCRs, which have identical antigen-binding sites and are both associated with the signaling subunits Ig-alpha and Ig-beta, but differ in their membrane-bound heavy chain isoforms.
Investigators at the BIOSS Centre for Biological Signaling Studies of the University of Freiburg (Germany) applied, two-color direct stochastic optical reconstruction microscopy (dSTORM), transmission electron microscopy (TEM), and the Fab-based proximity-ligation assay (Fab-PLA) to resolve the location and distribution of BCRs in the mature lymphocyte membrane.
Results published in the September 15, 2015, issue of the journal Science Signaling revealed that in contrast to the assumption that BCRs—like all proteins in the membrane—were freely diffusing molecules, dSTORM showed that IgM-BCRs and IgD-BCRs resided in the plasma membrane in different protein islands with average sizes of 150 and 240 nanometers, respectively. Upon B-cell activation, the BCR protein islands became smaller and more dispersed such that the IgM-BCRs and IgD-BCRs were found in close proximity to each other. Moreover, specific stimulation of one class of BCR had minimal effects on the organization of the other. These conclusions were supported by the findings from two-marker transmission electron microscopy and proximity ligation assays.
These results provide direct evidence for the nanoscale compartmentalization of the lymphocyte membrane. In addition, they suggest that upon B-cell activation, the different IgM and IgD protein islands form complexes, which allow the exchange of lipids and proteins. This could be the basis for the association of IgM with Raft-associated lipids and proteins, which is a well-known hallmark of B-cell activation.
The current study was a component of the University of Frieberg's BIOSS nanoscale explorer program (BiNEP), which is dedicated to developing better methods to resolve nano-structures that are smaller than the 250 nanometer diffraction limit of visible light.
Related Links:
BIOSS Centre for Biological Signaling Studies of the University of Freiburg
Latest BioResearch News
- Lung Cancer Study Reveals Cellular Program Behind Therapy Resistance
- Tumor Genome Marker May Predict Treatment Benefit in Pediatric Cancers
- Lysosomal Gene Defect Linked to Severe Childhood Brain Disorders
- Genetic Testing Identifies Greater Inherited Sudden Cardiac Arrest Risk in Younger Individuals
- Hidden 'Jumping Gene' Variant Linked to Higher Pancreatic Cancer Risk
- Common White Blood Cells Produce Schizophrenia-Linked Protein
- Nanopore Method Captures RNA Folding at Single-Molecule Resolution
- Tumor Microenvironment Marker Linked to Worse Survival in Solid Tumors
- Hidden Immune Gene Defect May Explain Kaposi Sarcoma Susceptibility
- Genetic Markers May Help Predict Amputation Risk in Peripheral Artery Disease
- Gene Signature Shows Promise for Depression Biomarker Testing
- AI-Driven Tumor Profiling Initiative Targets Precision Therapy Development
- Researchers Map Protein and Glycosylation Across 15 Human Body Fluids
- Telomere Length Abnormalities Linked to Lymphoma Development
- Biomarker Signals Chemotherapy Resistance in Relapsed Small Cell Lung Cancer
- Inflammatory Gene Signature Links Metabolic Disease to Pancreatic Cancer Recurrence
Channels
Clinical Chemistry
view channel
Urine-Based Test Shows Promise for Autism Screening in Children
Autism spectrum disorder (ASD) is commonly diagnosed through behavioral assessments, which can involve long waits that delay intervention. Earlier identification is linked to better developmental outcomes,... Read more
Liquid Biopsy Biomarkers May Improve Childhood Epilepsy Diagnosis
Childhood epilepsy remains a major neurological disorder with unmet needs for accurate, non-invasive biomarkers, as conventional tests such as electroencephalography and neuroimaging can have limited sensitivity... Read moreMolecular Diagnostics
view channel
Blood-Based MRD Monitoring Supports Relapse Prevention in Leukemia
In myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), molecular blood testing for minimal residual disease (MRD) can detect signs of impending relapse before clinical symptoms emerge.... Read more
Genomic Test Predicts Chemotherapy Benefit in Metastatic Prostate Cancer
Metastatic prostate cancer remains a major treatment challenge, particularly when deciding whether to add chemotherapy to hormonal therapy. In the United States, about 334,000 men are diagnosed with prostate... Read moreHematology
view channel
Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
Sysmex America (Chicago, IL, USA) has introduced the next generation XR-Series, centered on the XR-10 Automated Hematology Module for high-complexity laboratories. The platform builds on the widely used... Read more
Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
Immune checkpoint inhibitors have improved outcomes across many cancers, yet only a subset of patients derive durable benefit and biomarkers to guide treatment remain limited. Eosinophils, best known for... Read moreImmunology
view channel
Study Points to Autoimmune Pathway Behind Long COVID Symptoms
Long COVID leaves many SARS-CoV-2 survivors with persistent fatigue, cognitive issues, palpitations, and musculoskeletal pain for months or years. Estimates cited in new research suggest 4%–20% of infected... Read more
Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response
Tuberculosis (TB) remains the world’s leading infectious killer, with 10.8 million cases and 1.25 million deaths recorded globally in 2023. Yet many infected individuals never develop active disease, underscoring... Read moreMicrobiology
view channel
Gut Microbiome Signatures Help Identify Risk of IBD Progression
Inflammatory bowel disease (IBD), encompassing Crohn’s disease and ulcerative colitis, is a chronic relapsing inflammatory disorder of the gastrointestinal tract with highly variable outcomes.... Read more
FDA-Cleared Gastrointestinal Panel Detects 24 Pathogen Targets
Clinical guidelines support testing based on patient presentation in suspected gastrointestinal infections, yet available technologies have often forced laboratories to choose between panels that are too... Read morePathology
view channel
AI-Powered Atlas Maps Immune Structures Linked to Cancer Outcomes
Tertiary lymphoid structures are emerging as important indicators of antitumor immunity, but their heterogeneity and spatial context within tumors remain difficult to capture through routine diagnostics.... Read more
AI Tool Extracts Immune Signals from Biopsy to Inform Myeloma Therapy
Multiple myeloma is a bone marrow malignancy in which patients can respond very differently to the same treatments, making initial therapy decisions difficult. Clinicians must choose among options such... Read moreTechnology
view channel
AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
Oncology teams must manage growing volumes of genomic data, rapidly evolving clinical trial options, and frequently updated care guidelines, all within tight clinic schedules. Translating complex tumor... Read more
Agentic AI Platform Supports Genomic Decision-Making in Oncology
Oncology care teams increasingly face the challenge of managing complex molecular diagnostics, evolving treatment options, and extensive electronic health record documentation. Translating multimodal data... Read moreIndustry
view channel








